Luneri

Lion's Mane clinical brief

Lion's Mane

Dossier liveB

Cognitive

CognitiveDossier-backed

Evidence strength

Established signal

4 RCTs - 7 tracked studies

What it is for

Mild cognitive impairment - cognitive function support

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Highest-signal biomarkers

Human linked

Research signal

Top caution

Cyclosporine

D

Theoretical immunostimulatory activity could reduce immunosuppressive efficacy in transplant or autoimmune patients; no clinical cases confirmed

Evidence index

68

Authored product-registry confidence score

Meta-analyses

0

Pooled human evidence

RCTs

4

Randomized clinical trials

Tracked studies

7

Studies currently mapped to this dossier

Clinical memoEstablished signal

Executive summary

Immediate brief

Lion's Mane is a Cognitive with its clearest current use in Mild cognitive impairment - cognitive function support.

Established signal human evidence supports the brief, anchored by 7 tracked studies, 4 RCTs.

Theoretical immunostimulatory activity could reduce immunosuppressive efficacy in transplant or autoimmune patients; no clinical cases confirmed Theoretical immunostimulatory activity could reduce immunosuppressive efficacy in transplant or autoimmune patients; no clinical cases confirmed Evidence cannot be straightforwardly extrapolated to Western populations; dietary context (traditional mushroom consumption vs.

Anchor decision

Mild cognitive impairment - cognitive function support

Best current human use case

Confidence

Established signal

4 RCTs - 7 tracked studies

Read next

Cyclosporine

Pressure-test the lead caution before acting.

Reading guide

How to use this brief

1. Orient

Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.

2. Pressure-test

Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.

3. Operationalize

Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.

Lion's ManeDossier liveBPrimary useMild cognitive impairment - cognitive function support
CautionCyclosporine

Major warning

D

Pregnancy

Overview

Clinical posture

Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.

Primary signal

Mechanism summary

Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.

NGF biosynthesis induction - hericenones (fruiting body) and erinacines A/C/E/F/G/S (mycelium) stimulate nerve growth factor synthesis in astrocytes and neuronal cells; downstream signaling via TrkA/Erk1/2 and PI3K-Akt pathways drives neurite outgrowth
NF-kB pathway inhibition - erinacine C suppresses IkBalpha phosphorylation (p-IkBalpha), blocking NF-kB nuclear translocation and downstream pro-inflammatory transcription (iNOS, IL-6, TNF-alpha)
Nrf2/HO-1 antioxidant pathway activation - erinacine C inhibits Keap1 protein, releasing Nrf2 for nuclear translocation; upregulates HO-1 expression conferring anti-neuroinflammatory and cytoprotective effects
iNOS suppression → reduced nitric oxide - erinacine C inhibits inducible nitric oxide synthase protein expression, reducing NO and peroxynitrite-mediated neuroinflammatory damage in activated microglia

Co-primary

Safety summary

These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.

Theoretical immunostimulatory activity could reduce immunosuppressive efficacy in transplant or autoimmune patients; no clinical cases confirmed
Pregnancy

Supporting context

Evidence scope

Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.

Generalizability

Review

Evidence cannot be straightforwardly extrapolated to Western populations; dietary context (traditional mushroom consumption vs.

Evidence scope

Review

Product standardization required before clinical recommendations.

Evidence scope

Review

Short-term trials underestimate efficacy; continuous use appears necessary; no data on long-term safety beyond 16 weeks in humans

Publication bias

Review

Current evidence base insufficient for clinical recommendations across any indication.

Synergies

Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.

No validated pairing data yet

Declared

No dossier-backed pairing evidence is currently mapped for Lion's Mane.

Research unknowns

These are the open questions that still keep the compound from reading like a closed case.

Does oral lion's mane supplementation measurably increase serum or CSF NGF levels in humans?
What are the oral bioavailability, Tmax, Cmax, and tissue distribution profiles of hericenones and erinacines in humans?
Do APOE ε4 carriers respond differently to lion's mane supplementation for cognitive outcomes?
Is there any cognitive benefit of lion's mane in healthy adults without MCI or AD?